ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

10051	Companies
205083	Keywords
135323	Articles
108730	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 11/03/2025 at 22:05, 4 months 15 days ago

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
Abivax announces significant improvements in quality of life for patients with ulcerative colitis in Phase 3 ABTECT induction trials of Obefazimod, incorporating patient-reported outcomes data

Abivax Obefazimod Ulcerative Colitis Phase 3 Patient-reported Outcomes
BRIEF

published on 10/24/2025 at 09:41, 4 months 25 days ago

JP Morgan Chase & Co. Crosses the 5% Threshold at ABIVAX

Voting Rights Capital Abivax Crossing Thresholds JP Morgan
BRIEF

published on 10/15/2025 at 18:05, 5 months 3 days ago

ABIVAX: Status of shares and voting rights as of September 30, 2025

Share Capital Voting Rights Biotechnology Euronext Abivax
BRIEF

published on 10/13/2025 at 14:50, 5 months 5 days ago

JP Morgan exceeds the 5% threshold at ABIVAX

Voting Rights Actions Abivax Threshold Crossing JP Morgan
BRIEF

published on 10/06/2025 at 10:05, 5 months 12 days ago

Abivax Unveils Promising New Results from Obefazimod

Abivax Obefazimod Ulcerative Colitis Clinical Trial Results
PRESS RELEASE

published on 10/06/2025 at 10:00, 5 months 12 days ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
Abivax announces late-breaking presentation at UEG Meeting on ABTECT Induction Trial results in patients with and without prior inadequate response to advanced therapies. Obefazimod shows clinically meaningful improvements and favorable safety profile

Abivax Obefazimod Ulcerative Colitis Clinical Trial Late-breaking Presentation
BRIEF

published on 10/05/2025 at 17:05, 5 months 13 days ago

Abivax Presents Promising 8-Week ABTECT Trial Results

Abivax Obefazimod Ulcerative Colitis Clinical Trials Safety Data
PRESS RELEASE

published on 10/05/2025 at 17:00, 5 months 13 days ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax announces positive results from Phase 3 ABTECT 8-Week Induction Trials on obefazimod for ulcerative colitis treatment with no new safety concerns identified, to present further abstract on October 6

Abivax Obefazimod Ulcerative Colitis Phase 3 Trial Safety Data
BRIEF

published on 10/03/2025 at 11:59, 5 months 15 days ago

JP Morgan Chase & Co. crosses the 5% threshold at ABIVAX

Voting Rights Actions Abivax Threshold Crossing JP Morgan
BRIEF

published on 09/29/2025 at 22:10, 5 months 19 days ago

Abivax Presents New Findings on Obefazimod at UEG 2025

Abivax Obefazimod Ulcerative Colitis Phase 3 Trials UEG Meeting

Accesswire

Published on 03/19/2026 at 01:05, 2 hours 35 minutes ago

Prospect Ridge Announces Closing of Flow-Through Share Private Placement
Published on 03/18/2026 at 23:45, 3 hours 55 minutes ago

Orogen Royalties Announces Private Placement Update
Published on 03/18/2026 at 21:00, 6 hours 40 minutes ago

PLDT's Smart Selects Amdocs to Transform Retail Operations with AI-Powered Store Genie
Published on 03/18/2026 at 19:05, 8 hours 35 minutes ago

Deposit Modeling at Thor Shows that the Proven Thor Epithermal Deposit is Flanked on Both Sides by a Much Larger Deposit
Published on 03/18/2026 at 18:10, 9 hours 30 minutes ago

Silver X Mining Closes C$69M Brokered Private Placement of Secured Convertible Debentures

View all ACCESSWIRE

EQS Group

Published on 03/18/2026 at 22:00, 5 hours 40 minutes ago

aap successfully completes MDR certification: All existing products approved according to MDR – market access in the EU and CE-relevant markets secured in the long term
Published on 03/18/2026 at 18:53, 8 hours 46 minutes ago

EQS-Adhoc: Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025
Published on 03/18/2026 at 18:37, 9 hours 3 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/18/2026 at 18:27, 9 hours 12 minutes ago

POS-Transaction in Own Shares
Published on 03/18/2026 at 18:15, 9 hours 24 minutes ago

Northern Data Group releases audited FY 2025 Financial Results

Les Echos

Published on 03/18/2026 at 19:41, 7 hours 58 minutes ago

Covivio - Conditions of availability of the 2025 Universal Registration Document
Published on 03/18/2026 at 18:00, 9 hours 40 minutes ago

Deezer achieves profitability in FY25 as strategy delivers tangible results
Published on 03/18/2026 at 17:45, 9 hours 55 minutes ago

Infotel : 2025 full-year results. Launch of a new Infotel 2030 strategic plan. Revenue target of €500 million by 2030.
Published on 03/18/2026 at 17:40, 10 hours ago

260318 BENETEAU Presentation FY 2025
Published on 03/18/2026 at 17:40, 10 hours ago

260318 BENETEAU FY 2025 Results

View all LES ECHOS COMFI WIRE